Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|July 16, 2009
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerF Loupakis, A Ruzzo, C Cremolini, et al.
ESMO Open|January 10, 2021
Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapyM Ganzinelli, H Linardou, M F Alvisi, et al.
ESMO Open|December 4, 2022
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesotheliomaS Canova, G L Ceresoli, F Grosso, et al.
The Pharmacogenomics Journal|December 24, 2008
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancerF Graziano, A Ruzzo, E Canestrari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2020
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trialF Petrelli, E Rulli, R Labianca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2016
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trialS Lonardi, A Sobrero, G Rosati, et al.
ESMO Open|August 9, 2024
TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma GroupC Fabbroni, G Grignani, B Vincenzi, et al.
British Journal of Cancer|October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsA Ruzzo, F Graziano, Fabio Galli, et al.
ESMO Open|December 1, 2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkersG Lo Russo, F Sgambelluri, A Prelaj, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trialM G Ghi, A Paccagnella, D Ferrari, et al.
Pageof 5